Dana-Farber's Sara Tolaney, MD, MPH, provides insight on DESTINY-Breast09 trial highlighted at ESMO 2021.
And as well. This year I'm presenting a poster trials in progress poster called Destiny breast oh nine which will examine Trustees mob direct Stickin also known as T. D. XD. With or without Pertuzumab compared to a tax saying trust us a mob and Pertuzumab in the first line her two positive metastatic setting, we certainly know that the current standard of care for patients who have her two positive metastatic disease has been a tax laying with trust. Osama bin Pertuzumab in the first line setting. However many of our patients do ultimately develop treatment resistance and more first line treatment options are needed. T. D. X. D. Is an antibody drug conjugate that has proven to be highly effective based on data that we've seen from Destiny breast. A one as well as Mueller recently from Destiny breast oh three. And so given these results, there's a lot of encouraging activity to suggest that TTXT maybe a replacement for THP and in fact may do better with or without Pertuzumab. And so that is what this study is exploring and this trial is currently enrolling. And so we're very excited to see what it will find
